{"id":52190,"date":"2026-03-24T19:30:00","date_gmt":"2026-03-24T12:30:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=52190"},"modified":"2026-03-24T19:30:00","modified_gmt":"2026-03-24T12:30:00","slug":"hkeybio-launches-hkey-nhp-onchip-1-1-worlds-first-nhp-in-vitro-model-for-autoimmune-and-allergic-diseases","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=52190","title":{"rendered":"HKeyBio Launches HKEY-NHP-onChip\u2122 1.1: World&#8217;s First NHP In Vitro Model for Autoimmune and Allergic Diseases"},"content":{"rendered":"<p class=\"prntac\"><b><span>The\u00a0integrated\u00a0organ-on-chip\u00a0platform\u00a0offers\u00a010\u2013100x\u00a0cost\u00a0efficiency\u00a0and\u00a080%\u00a0reduction\u00a0in\u00a0animal\u00a0use,\u00a0bridging\u00a0the\u00a0gap\u00a0between\u00a0preclinical\u00a0NHP\u00a0research\u00a0and\u00a0human\u00a0clinical\u00a0success.<\/span><\/b><\/p>\n<p><span class=\"legendSpanClass\">SUZHOU, China, SAN FRANCISCO and BOSTON<\/span>, <span class=\"legendSpanClass\">March 24, 2026<\/span> \/PRNewswire\/ &#8212; HKeyBio, a global leading CRO specializing in preclinical and translational research for autoimmune and allergic diseases, today officially announced the launch of its HKEY-NHP-onChip\u2122 1.1 platform \u2014 the world&#8217;s first non-human primate (NHP) in vitro model system dedicated to autoimmune and allergic diseases.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mma.prnasia.com\/media2\/2940888\/HKeyBio.html\" target=\"_blank\" rel=\"nofollow\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2940888\/HKeyBio.jpg?p=medium600\" title=\"HKEY-NHP-onChip\u2122 1.1\" alt=\"HKEY-NHP-onChip\u2122 1.1\" \/> <\/a> <br \/><span>HKEY-NHP-onChip\u2122 1.1<\/span><\/p>\n<\/div>\n<p>The platform integrates non-human primate-derived organoids, organ-on-chip technologies, and immune\u2013tissue co-culture systems, successfully enabling a strategic transition from traditional in vivo animal studies to high-throughput in vitro research.<\/p>\n<p>According to data published in Nature Reviews Drug Discovery (2024), the development of new drugs for autoimmune diseases typically takes 10\u201315 years, with an average cost of approximately $2.6 billion. Model selection during the preclinical stage plays a critical role in downstream translational success.<\/p>\n<p>While maintaining the high translational value of NHP models, the HKEY-NHP-onChip\u2122 1.1 platform reduces single-experiment costs by 10\u2013100\u00d7, providing innovative biotech companies with a breakthrough solution that balances scientific rigor and capital efficiency.<\/p>\n<p><b>Market Pain Point: Structural Gap in\u00a0NHP In Vitro Models<\/b><\/p>\n<p>Drug development for autoimmune and allergic diseases has long faced a structural bottleneck.<\/p>\n<p>According to the PhRMA 2024 industry report, the global autoimmune disease drug market is projected to grow from $145 billion in 2024 to $218 billion by 2030, representing a CAGR of 7.1%. However, drug development success rates continue to decline:<\/p>\n<ul type=\"disc\">\n<li>Rodent models differ significantly from human disease mechanisms. FDA data indicate that approximately 90% of drug candidates fail during clinical trials, with insufficient predictive power of preclinical models being a major factor.<\/li>\n<li>High cost of NHP in vivo models: the procurement cost of a single cynomolgus monkey exceeds RMB 100,000, and a typical pharmacology study requires 20\u201350 animals.<\/li>\n<li>High inter-individual variability: coefficient of variation (CV) of traditional in vivo studies typically ranges from 30\u201350%, affecting data reliability.<\/li>\n<\/ul>\n<p><i>&#8220;When we evaluated current market offerings, we identified a clear disconnect,&#8221; said the CSO of HKeyBio. &#8220;Generic organoid companies lack NHP resources and autoimmune\/allergy disease expertise; traditional CROs lack organoid and organ-on-chip technologies; and organ-chip startups often lack deep disease biology understanding. HKEY-NHP-onChip\u2122 1.1 was designed to bridge this gap \u2014 serving as both a natural extension of our existing NHP in vivo models and a bridge toward broader human disease applications.&#8221;<\/i><\/p>\n<p><b>Core Platform Architecture: A Three-Dimensional Integrated Design<\/b><\/p>\n<p><b>Dimension 1:\u00a0NHP-Derived In Vitro Model System<\/b><\/p>\n<p>Built on more than 10,000 in vivo experiments accumulated over the past decade, HKeyBio has established standardized NHP-derived in vitro models:<\/p>\n<ul type=\"disc\">\n<li>Cynomolgus monkey organoids, including intestinal organoids (&gt;85% differentiation success rate), skin organoids (14\u201321 day culture cycle), airway organoids, and additional tissue models<\/li>\n<li>NHP organ-on-chip systems simulating intestinal permeability, lung epithelial-immune interactions, and skin microenvironment<\/li>\n<li>NHP co-culture systems integrating immune cells (T cells, B cells, mast cells, myeloid cells) with full tissue reconstruction of skin, lung, and intestinal environments<\/li>\n<\/ul>\n<p><b>Dimension 2: Human Disease Modeling Platform<\/b><\/p>\n<p>The platform simultaneously establishes human in vitro disease models in collaboration with leading hospitals including Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine and Shanxi Provincial People&#8217;s Hospital, enabling cross-species validation.<\/p>\n<p><b>Dimension 3: In\u00a0Vivo\u2013In Vitro Data Mapping and Validation<\/b><\/p>\n<p>The platform has established a unique cross-validation system covering 12 diseases including asthma, COPD, atopic dermatitis, psoriasis, inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis, improving predictive reliability.<\/p>\n<p><b>Coverage of Four Major Disease Areas: First 12 Disease Models Launched<\/b><\/p>\n<p>According to Evaluate Pharma 2024, these disease areas represent core directions in autoimmune and allergic drug development. Targeted therapies such as IL-4R\u03b1, IL-23\/IL-17, and JAK inhibitors generated combined global sales exceeding $35 billion in 2023.<\/p>\n<p><b>Scientific Value and Commercial Advantages<\/b><\/p>\n<ul type=\"disc\">\n<li>10\u2013100\u00d7 cost reduction<\/li>\n<li>60\u201380% reduction in animal use<\/li>\n<li>Variability reduced from 30\u201350% to 15\u201325%<\/li>\n<li>Single-cell resolution mechanistic insights<\/li>\n<li>10\u2013100\u00d7 throughput increase<\/li>\n<li>Predictive accuracy improved to 75\u201382%<\/li>\n<\/ul>\n<p><i>&#8220;HKeyBio has accumulated deep disease biology insights and extensive in vivo data assets in NHP autoimmune and allergic disease models,&#8221; commented Professor Huili Lu. &#8220;The unique value of HKEY-NHP-onChip\u2122 1.1 lies in its seamless integration with existing in vivo models. This dual-track strategy represents the optimal paradigm for next-generation CRO services.&#8221;<\/i><\/p>\n<p><b>Technology Roadmap<\/b><\/p>\n<p><b>Phase 1: Validation (Completed, 2024\u20132025)<\/b><\/p>\n<ul type=\"disc\">\n<li>Six disease models validated<\/li>\n<li>Standardized SOP and ISO 9001 quality system established<\/li>\n<li>Long-term agreements with 2\u20133 NHP suppliers<\/li>\n<li>Three publications submitted and two patents filed<\/li>\n<\/ul>\n<p><b>Phase 2: Expansion (2025\u20132026, Current Stage)<\/b><\/p>\n<ul type=\"disc\">\n<li>12 disease models launched<\/li>\n<li>Patient-derived organoid biobank (target: 500 samples)<\/li>\n<li>Clinical collaborations with 5\u20138 hospitals<\/li>\n<li>Initial commercial project delivery completed<\/li>\n<\/ul>\n<p><b>Phase 3: Intelligent Upgrade (2026\u20132027)<\/b><\/p>\n<ul type=\"disc\">\n<li>Automated organoid culture systems<\/li>\n<li>High-throughput liquid handling robotics<\/li>\n<li>100,000+ data point database<\/li>\n<li>AI predictive models for efficacy and toxicity<\/li>\n<li>Industry standards for NHP in vitro models<\/li>\n<\/ul>\n<p><b>Business Model and Service Capabilities<\/b><\/p>\n<p><b>Custom Model Development<\/b><\/p>\n<ul type=\"disc\">\n<li>Service timeline: 3\u20136 months<\/li>\n<li>Deliverables: standardized model, full methodology report<\/li>\n<li>Use cases: target validation, novel mechanism exploration<\/li>\n<\/ul>\n<p><b>High-Throughput Drug Screening<\/b><\/p>\n<ul type=\"disc\">\n<li>Hundreds to thousands of compounds per week<\/li>\n<li>SAR studies and lead optimization<\/li>\n<li>Dose-response curves and IC50\/EC50<\/li>\n<\/ul>\n<p><b>Mechanism and Biomarker Discovery<\/b><\/p>\n<ul type=\"disc\">\n<li>Single-cell sequencing<\/li>\n<li>Spatial transcriptomics<\/li>\n<li>High-content imaging<\/li>\n<li>Flow cytometry<\/li>\n<\/ul>\n<p><b>Integrated In Vitro\u2013In\u00a0Vivo Service Package<\/b><\/p>\n<ul type=\"disc\">\n<li>In vitro screening \u2192 in vivo validation \u2192 translational strategy<\/li>\n<li>Reduced development risk<\/li>\n<li>Ideal for milestone and IPO projects<\/li>\n<\/ul>\n<p><b>Strategic Vision<\/b><\/p>\n<p>HKeyBio positions itself as a strategic preclinical partner for next-generation autoimmune and allergic therapies. The launch of HKEY-NHP-onChip\u2122 1.1 marks HKeyBio&#8217;s transformation from an NHP in vivo model expert to an integrated in vivo\u2013in vitro research platform.<\/p>\n<p><i>&#8220;Our clients don&#8217;t lack data \u2014 they need clarity and actionable insight,&#8221; said the CSO of HKeyBio. &#8220;HKEY-NHP-onChip\u2122 1.1 enables earlier-stage decision making, lower cost, and higher-throughput data generation to support rational Go\/No-Go decisions.&#8221;<\/i><\/p>\n<p><b>About\u00a0HKeyBio<\/b><\/p>\n<p>HKeyBio is a leading CRO focused on autoimmune and allergic diseases, headquartered in Suzhou, China, with business offices in San Francisco and Boston.<\/p>\n<p>Core technology platforms include:<\/p>\n<ul type=\"disc\">\n<li>HKEY-NHP-MATRIX 2.0 \u2014 NHP disease model matrix covering 30+ diseases<\/li>\n<li>HKEY-AIDMD 3.0 \u2014 autoimmune disease model database with 10,000+ studies<\/li>\n<li>HKEY-AIRx\u2122 1.0 \u2014 translational preclinical strategy platform<\/li>\n<li>HKEY-NHP-onChip\u2122 1.1 \u2014 NHP-derived in vitro organoid + organ-chip platform<\/li>\n<\/ul>\n<p>HKeyBio provides end-to-end research services from target validation to IND submission for global biotech and pharmaceutical companies.<\/p>\n<p>For more information, visit: <a href=\"https:\/\/www.hkeybio.com\/\" target=\"_blank\" rel=\"nofollow\">www.hkeybio.com<\/a> Email: <a href=\"mailto:tech@hkeybio.com\" target=\"_blank\" rel=\"nofollow\">tech@hkeybio.com<\/a>\u00a0<\/p>\n<p><span>All data cited<\/span> in this press release are derived from publicly available academic literature and industry reports including Nature Reviews Drug Discovery, PhRMA, Evaluate Pharma, and FDA publications.<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p class=\"prntac\"><b><span>The\u00a0integrated\u00a0organ-on-chip\u00a0platform\u00a0offers\u00a010\u2013100x\u00a0cost\u00a0efficiency\u00a0and\u00a080%\u00a0reduction\u00a0in\u00a0animal\u00a0use,\u00a0bridging\u00a0the\u00a0gap\u00a0between\u00a0preclinical\u00a0NHP\u00a0research\u00a0and\u00a0human\u00a0clinical\u00a0success.<\/span><\/b><\/p>\n<p><span class=\"legendSpanClass\">SUZHOU, China, SAN FRANCISCO and BOSTON<\/span>, <span class=\"legendSpanClass\">March 24, 2026<\/span> \/PRNewswire\/ &#8212; HKeyBio, a global leading CRO specializing in preclinical and translational research for autoimmune and allergic diseases, today officially announced the launch of its HKEY-NHP-onChip\u2122 1.1 platform \u2014 the world&#8217;s first non-human primate (NHP) in vitro model system dedicated to autoimmune and allergic diseases.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mma.prnasia.com\/media2\/2940888\/HKeyBio.html\" target=\"_blank\" rel=\"nofollow\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2940888\/HKeyBio.jpg?p=medium600\" title=\"HKEY-NHP-onChip\u2122 1.1\" alt=\"HKEY-NHP-onChip\u2122 1.1\" \/> <\/a> <br \/><span>HKEY-NHP-onChip\u2122 1.1<\/span><\/p>\n<\/div>\n<p>The platform integrates non-human primate-derived organoids, organ-on-chip technologies, and immune\u2013tissue co-culture systems, successfully enabling a strategic transition from traditional in vivo animal studies to high-throughput in vitro research.<\/p>\n<p>According to data published in Nature Reviews Drug Discovery (2024), the development of new drugs for autoimmune diseases typically takes 10\u201315 years, with an average cost of approximately $2.6 billion. Model selection during the preclinical stage plays a critical role in downstream translational success.<\/p>\n<p>While maintaining the high translational value of NHP models, the HKEY-NHP-onChip\u2122 1.1 platform reduces single-experiment costs by 10\u2013100\u00d7, providing innovative biotech companies with a breakthrough solution that balances scientific rigor and capital efficiency.<\/p>\n<p><b>Market Pain Point: Structural Gap in\u00a0NHP In Vitro Models<\/b><\/p>\n<p>Drug development for autoimmune and allergic diseases has long faced a structural bottleneck.<\/p>\n<p>According to the PhRMA 2024 industry report, the global autoimmune disease drug market is projected to grow from $145 billion in 2024 to $218 billion by 2030, representing a CAGR of 7.1%. However, drug development success rates continue to decline:<\/p>\n<ul type=\"disc\">\n<li>Rodent models differ significantly from human disease mechanisms. FDA data indicate that approximately 90% of drug candidates fail during clinical trials, with insufficient predictive power of preclinical models being a major factor.<\/li>\n<li>High cost of NHP in vivo models: the procurement cost of a single cynomolgus monkey exceeds RMB 100,000, and a typical pharmacology study requires 20\u201350 animals.<\/li>\n<li>High inter-individual variability: coefficient of variation (CV) of traditional in vivo studies typically ranges from 30\u201350%, affecting data reliability.<\/li>\n<\/ul>\n<p><i>&#8220;When we evaluated current market offerings, we identified a clear disconnect,&#8221; said the CSO of HKeyBio. &#8220;Generic organoid companies lack NHP resources and autoimmune\/allergy disease expertise; traditional CROs lack organoid and organ-on-chip technologies; and organ-chip startups often lack deep disease biology understanding. HKEY-NHP-onChip\u2122 1.1 was designed to bridge this gap \u2014 serving as both a natural extension of our existing NHP in vivo models and a bridge toward broader human disease applications.&#8221;<\/i><\/p>\n<p><b>Core Platform Architecture: A Three-Dimensional Integrated Design<\/b><\/p>\n<p><b>Dimension 1:\u00a0NHP-Derived In Vitro Model System<\/b><\/p>\n<p>Built on more than 10,000 in vivo experiments accumulated over the past decade, HKeyBio has established standardized NHP-derived in vitro models:<\/p>\n<ul type=\"disc\">\n<li>Cynomolgus monkey organoids, including intestinal organoids (&gt;85% differentiation success rate), skin organoids (14\u201321 day culture cycle), airway organoids, and additional tissue models<\/li>\n<li>NHP organ-on-chip systems simulating intestinal permeability, lung epithelial-immune interactions, and skin microenvironment<\/li>\n<li>NHP co-culture systems integrating immune cells (T cells, B cells, mast cells, myeloid cells) with full tissue reconstruction of skin, lung, and intestinal environments<\/li>\n<\/ul>\n<p><b>Dimension 2: Human Disease Modeling Platform<\/b><\/p>\n<p>The platform simultaneously establishes human in vitro disease models in collaboration with leading hospitals including Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine and Shanxi Provincial People&#8217;s Hospital, enabling cross-species validation.<\/p>\n<p><b>Dimension 3: In\u00a0Vivo\u2013In Vitro Data Mapping and Validation<\/b><\/p>\n<p>The platform has established a unique cross-validation system covering 12 diseases including asthma, COPD, atopic dermatitis, psoriasis, inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis, improving predictive reliability.<\/p>\n<p><b>Coverage of Four Major Disease Areas: First 12 Disease Models Launched<\/b><\/p>\n<p>According to Evaluate Pharma 2024, these disease areas represent core directions in autoimmune and allergic drug development. Targeted therapies such as IL-4R\u03b1, IL-23\/IL-17, and JAK inhibitors generated combined global sales exceeding $35 billion in 2023.<\/p>\n<p><b>Scientific Value and Commercial Advantages<\/b><\/p>\n<ul type=\"disc\">\n<li>10\u2013100\u00d7 cost reduction<\/li>\n<li>60\u201380% reduction in animal use<\/li>\n<li>Variability reduced from 30\u201350% to 15\u201325%<\/li>\n<li>Single-cell resolution mechanistic insights<\/li>\n<li>10\u2013100\u00d7 throughput increase<\/li>\n<li>Predictive accuracy improved to 75\u201382%<\/li>\n<\/ul>\n<p><i>&#8220;HKeyBio has accumulated deep disease biology insights and extensive in vivo data assets in NHP autoimmune and allergic disease models,&#8221; commented Professor Huili Lu. &#8220;The unique value of HKEY-NHP-onChip\u2122 1.1 lies in its seamless integration with existing in vivo models. This dual-track strategy represents the optimal paradigm for next-generation CRO services.&#8221;<\/i><\/p>\n<p><b>Technology Roadmap<\/b><\/p>\n<p><b>Phase 1: Validation (Completed, 2024\u20132025)<\/b><\/p>\n<ul type=\"disc\">\n<li>Six disease models validated<\/li>\n<li>Standardized SOP and ISO 9001 quality system established<\/li>\n<li>Long-term agreements with 2\u20133 NHP suppliers<\/li>\n<li>Three publications submitted and two patents filed<\/li>\n<\/ul>\n<p><b>Phase 2: Expansion (2025\u20132026, Current Stage)<\/b><\/p>\n<ul type=\"disc\">\n<li>12 disease models launched<\/li>\n<li>Patient-derived organoid biobank (target: 500 samples)<\/li>\n<li>Clinical collaborations with 5\u20138 hospitals<\/li>\n<li>Initial commercial project delivery completed<\/li>\n<\/ul>\n<p><b>Phase 3: Intelligent Upgrade (2026\u20132027)<\/b><\/p>\n<ul type=\"disc\">\n<li>Automated organoid culture systems<\/li>\n<li>High-throughput liquid handling robotics<\/li>\n<li>100,000+ data point database<\/li>\n<li>AI predictive models for efficacy and toxicity<\/li>\n<li>Industry standards for NHP in vitro models<\/li>\n<\/ul>\n<p><b>Business Model and Service Capabilities<\/b><\/p>\n<p><b>Custom Model Development<\/b><\/p>\n<ul type=\"disc\">\n<li>Service timeline: 3\u20136 months<\/li>\n<li>Deliverables: standardized model, full methodology report<\/li>\n<li>Use cases: target validation, novel mechanism exploration<\/li>\n<\/ul>\n<p><b>High-Throughput Drug Screening<\/b><\/p>\n<ul type=\"disc\">\n<li>Hundreds to thousands of compounds per week<\/li>\n<li>SAR studies and lead optimization<\/li>\n<li>Dose-response curves and IC50\/EC50<\/li>\n<\/ul>\n<p><b>Mechanism and Biomarker Discovery<\/b><\/p>\n<ul type=\"disc\">\n<li>Single-cell sequencing<\/li>\n<li>Spatial transcriptomics<\/li>\n<li>High-content imaging<\/li>\n<li>Flow cytometry<\/li>\n<\/ul>\n<p><b>Integrated In Vitro\u2013In\u00a0Vivo Service Package<\/b><\/p>\n<ul type=\"disc\">\n<li>In vitro screening \u2192 in vivo validation \u2192 translational strategy<\/li>\n<li>Reduced development risk<\/li>\n<li>Ideal for milestone and IPO projects<\/li>\n<\/ul>\n<p><b>Strategic Vision<\/b><\/p>\n<p>HKeyBio positions itself as a strategic preclinical partner for next-generation autoimmune and allergic therapies. The launch of HKEY-NHP-onChip\u2122 1.1 marks HKeyBio&#8217;s transformation from an NHP in vivo model expert to an integrated in vivo\u2013in vitro research platform.<\/p>\n<p><i>&#8220;Our clients don&#8217;t lack data \u2014 they need clarity and actionable insight,&#8221; said the CSO of HKeyBio. &#8220;HKEY-NHP-onChip\u2122 1.1 enables earlier-stage decision making, lower cost, and higher-throughput data generation to support rational Go\/No-Go decisions.&#8221;<\/i><\/p>\n<p><b>About\u00a0HKeyBio<\/b><\/p>\n<p>HKeyBio is a leading CRO focused on autoimmune and allergic diseases, headquartered in Suzhou, China, with business offices in San Francisco and Boston.<\/p>\n<p>Core technology platforms include:<\/p>\n<ul type=\"disc\">\n<li>HKEY-NHP-MATRIX 2.0 \u2014 NHP disease model matrix covering 30+ diseases<\/li>\n<li>HKEY-AIDMD 3.0 \u2014 autoimmune disease model database with 10,000+ studies<\/li>\n<li>HKEY-AIRx\u2122 1.0 \u2014 translational preclinical strategy platform<\/li>\n<li>HKEY-NHP-onChip\u2122 1.1 \u2014 NHP-derived in vitro organoid + organ-chip platform<\/li>\n<\/ul>\n<p>HKeyBio provides end-to-end research services from target validation to IND submission for global biotech and pharmaceutical companies.<\/p>\n<p>For more information, visit: <a href=\"https:\/\/www.hkeybio.com\/\" target=\"_blank\" rel=\"nofollow\">www.hkeybio.com<\/a> Email: <a href=\"mailto:tech@hkeybio.com\" target=\"_blank\" rel=\"nofollow\">tech@hkeybio.com<\/a>\u00a0<\/p>\n<p><span>All data cited<\/span> in this press release are derived from publicly available academic literature and industry reports including Nature Reviews Drug Discovery, PhRMA, Evaluate Pharma, and FDA publications.<\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-52190","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/52190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52190"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/52190\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}